RR-TB | Second-line HIV | COVID-19 | Total | |
Enrolled in class | 62 | 28 | 16 | 106 |
Participated (n (%)) | 55 (89) | 25 (89) | 15 (94) | 95 (90) |
Age (median (range)) | 35 (27–50) | 36 (27–45) | 37 (28–45) | 35 (27–50) |
Gender (n (%)) | ||||
Female | 30 (48) | 11 (39) | 5 (31) | 46 (43) |
Male | 32 (52) | 17 (61) | 11 (69) | 60 (57) |
Continent (n (%)) | ||||
Europe | 10 (16) | 2 (7) | 2 (13) | 14 (13) |
Africa | 33 (53) | 22 (79) | 13 (81) | 68 (64) |
Asia | 17 (27) | 3 (11) | 1 (6) | 21 (20) |
Americas | 2 (3) | 1 (4) | 0 (0) | 3 (3) |
Degree (n (%)) | ||||
MD/MBBS | 60 (97) | 22 (79) | 15 (94) | 97 (92) |
Continued education* | 35 (56) | 13 (46) | 3 (19) | 51 (48) |
*Any postgraduate degree other than MD/MBBS, for example, MPH, MSc, specialisation, PhD.
aNGT, adapted nominal group technique; RR-TB, rifampicin-resistant tuberculosis.